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Edited by Richard MaraisAbstract The hypoxia responsive region (HRR) of the VEGF
promoter plays a key role in regulating VEGF expression. We
found that the cold shock domain (Y-box) repressor proteins,
dbpA and dbpB/YB-1, bind distinct strands of the human VEGF
HRR. We ﬁnd both dbpA and dbpB are phosphorylated by
ERK2 and GSK3b in vitro, and the binding of dbpB to single-
strand VEGF HRR DNA is regulated by this phosphorylation.
These ﬁndings suggest the ERK/MAPK and PI3K pathways
may regulate VEGF expression in part through regulating the
action of these repressor proteins.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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VEGF is a key regulator of angiogenesis whose expression is
important in the development and maintenance of solid tu-
mors. The hypoxia responsive region (HRR) of the VEGF
promoter plays a major role in regulating VEGF expression.
It is responsive to hypoxia, oncoproteins and growth factors,
primarily via activation of function of the positive activator
HIF-1 (hypoxia inducible factor 1) through mechanisms tar-
geting the HIF-1a subunit of the HIF-1 complex [1–3]. Signal-
ling to the VEGF HRR can involve both ERK/MAPK
(mitogen-activated protein kinase) and PI3K (phosphatidylin-
ositol 3-kinase)/Akt signalling pathways [1,3,4].
A number of proteins, including VHL, prolyl hydroxylases
and the HDM2/p53 pathway, negatively regulate VEGF
expression by targeting HIF-1a for degradation when oxygen
levels are adequate [5–7]. We recently identiﬁed an additional
mode of negative regulation of VEGF expression which in-
volves transcriptional repression by members of the cold
shock domain (CSD) family of proteins (also known as Y-
box proteins) [8]. CSD proteins are primarily single-strandAbbreviations: CSD, cold shock domain; HRR, hypoxia responsive
region; PI3K, phosphatidylinositol 3-kinase; MAPK, mitogen-acti-
vated protein kinase
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doi:10.1016/j.febslet.2005.08.075DNA and RNA binding proteins involved in both transcrip-
tional activation and repression, and which also operate at
multiple levels in post-transcriptional regulation [9–11]. The
two major somatic CSD proteins are dbpB (also known as
YB-1, p50, MSY-1, TSEP1, NSEP1) and dbpA (also known
as YB-2, ZONAB, MSY3/4). We previously found these pro-
teins contact a site immediately downstream of the HIF-1
binding site on the non-coding strand of the mouse VEGF
HRR, and repress transcription from the VEGF HRR in
mouse ﬁbroblasts [8].
We now report an analysis of the human VEGF HRR in the
MCF-7 human breast cancer cell line. We ﬁnd that the dbpA
and dbpB CSD proteins bind to separate strands of the human
HRR, and furthermore that transcriptional repression medi-
ated by these proteins may be regulated by phosphorylation.2. Materials and methods
2.1. Plasmid constructs
The wild type and mutant human VEGF HRR luciferase reporter
constructs were constructed by cloning oligonucleotides shown in
Fig. 1 into BamHI/XhoI-digested pTK81luc as described previously
[8]. Background luciferase activity from pTK81luc does not respond
to hypoxia and is not aﬀected by CSD protein overexpression [8,12].
The plasmids pSGdbpA, pSGdbpB, GST-dbpA, GST-dbpB, pSGB-
del1 and pSGBdel2 were previously described [8,12]. pGEXBdel1
was generated by cloning EcoRI/NotI fragments from pSGBdel1 into
pGEX4T-1. pGEXAdel1 was created by digesting pGEXA with
NaeI/SmaI to remove the C-terminal and central CSD domains fol-
lowed by religation. pGEXAdel1 contains the ﬁrst 77 amino acids of
dbpA. dbpA and dbpB GST-peptide fusion constructs, pGEXA-ps
and pGEXB-ps contain, respectively, N-terminal amino acids 27–43
and 23–40. PGEXA-psmut and pGEXB-psmut contain ser/thr to ala
substitutions in ERK2 and GSK3b phosphorylation sites.
2.2. Preparation of recombinant and nuclear protein
The Escherichia coli strain MC1061 transformed with pGEXBT or
pGEXA was induced with isopropyl-1-thio-b-D-galactopyranoside to
produce recombinant GST-dbpB and -dbpA, respectively. The fu-
sion proteins were puriﬁed on glutathione–Sepharose beads as de-
scribed by the manufacturer (Promega). Crude nuclear extracts
from human MCF-7 breast cancer cells were prepared as previously
described [8].
2.3. Antibodies
An anti-CSD peptide polyclonal antibody was raised by immunizing
rabbits with the peptide (IKKNNPRKYLRSVGD) (human dbpB
amino acids 89–103, conserved in dbpA and dbpB) conjugated to key-
hole limpet hemocyanin (Imject conjugation kit, Pierce) as previously
described [12,8].blished by Elsevier B.V. All rights reserved.
Fig. 1. Sequences of gel shift oligonucleotides and reporter construct inserts from the human VEGF promoter. The sequence of the human VEGF
HRR (987 to 937, corresponding to 1376–1420 of GenBank M63971) is shown with the HIF-1 binding site [13] underlined, and predicted core
binding sequences for CSD proteins circled. The coding (+) and non-coding () strands are indicated. Bases that vary from the wild type sequence
are indicated, with wild type bases shown as dashes.
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Gel shift assays were performed using 0.25 ng of single-strand 32P-
labelled oligonucleotide probe in a 10 ll reaction mix of 0.5· TM
buﬀer containing 200 mM KCl, 0.4 lg of poly(dI-dC) and either
1 lg of crude nuclear extract or 25 ng of recombinant CSD fusion
protein (GST-dbpB, GST-dbpA), as described [9,8]. Gel shift assays
using recombinant protein also contained 2 lg of bovine serum albu-
min. Reactions were incubated at room temperature for 20 min and
analyzed on 12% or 6% non-denaturing polyacrylamide gels for
analysis of nuclear extracts and recombinant protein, respectively.
Competition with unlabelled single-strand oligonucleotides was per-
formed by addition of protein and 5 ng of unlabelled probe, fol-
lowed by immediate addition of the 32P-labelled probe. Antibody
blocking experiments were performed by adding protein and anti-
body and incubating for 5 min at room temperature before adding
the 32P-labelled probe. The reaction was incubated for an additional
20 min at room temperature before being analyzed on polyacryl-
amide gels. Oligonucleotides used in retardation assays are shown
in Fig. 1.2.5. Analysis of phosphorylated recombinant CSD proteins
Recombinant GST-CSD fusion proteins (dbpA, dbpB/YB-1; 50 ng)
were assayed for phosphorylation by GSK3b or ERK2 using
[c-32P]ATP in an in vitro phosphorylation assay, as described by the
supplier (New England Biolab). Kinase reactions were examined by
SDS/PAGE and 32P-labelled proteins detected after exposure of gels
to X-ray ﬁlm. Proteins were sized relative to marker proteins. For
preparation of cold-kinased proteins, kinase reactions were performed
in the presence of 0.5 mM ATP in the absence or presence of GSK3b
or ERK2. Cold kinased or mock kinased proteins were then immedi-
ately analyzed in a gel shift reaction as described above.2.6. Cell culture and transfection
MCF-7 breast cancer cells were grown in Dulbeccos modiﬁed Ea-
gles medium and 10% fetal calf serum. 2 · 105 cells were transfected
with 500 ng of luciferase reporter constructs or cotransfected with
500 ng reporter constructs and 250 ng of dbpB (pSGdbpB) or dbpA
(pSGdbpA) overexpression constructs. Transfections were performed
using Lipofectamine 2000 (Gibco BRL) according to the manufac-
turers directions. 24 hours after transfection, cells were either placed
in hypoxic conditions (1% O2) or left in normoxic conditions (20%
O2) for 16 h. For treatment with kinase pathway inhibitors, 50 lM
PD98059 or LY294002 (Promega) in DMSO or DMSO alone (ﬁnal
concentration 0.05%) were added 30 min prior to treatment. Hypoxic
conditions were generated in a hypoxic chamber (Edwards Instrument
Company, Sydney, Australia). Luciferase activity was determined as
previously described [8].3. Results
3.1. Strand-speciﬁc binding of dbpA and dbpB/YB-1 to the
human VEGF HR region
Having found previously that CSD proteins repress mouse
VEGF transcription by binding to single-stranded elements
in the HRR [8], we wished to check that the human VEGF
gene is subject to similar regulation. First we assessed the bind-
ing of recombinant GST-dbpA and GST-dbpB/YB-1 to indi-
vidual strands of the human VEGF HRR in gel shift assays.
GST-dbpA preferentially bound the HRR lower strand probe
(i.e., the non-coding strand, V5), whereas GST-dbpB prefer-
entially bound the coding strand (V5+) (Fig. 2A).
To examine whether CSD proteins in nuclear extracts
from MCF-7 human breast cancer cells can participate in
complex formation on the individual human HRR strands,
we performed gel shift assays in the presence or absence
of an inhibitory anti-CSD antibody [8,12] or preimmune ser-
um. The major complexes that formed on each strand were
distinct, but their respective formations were strongly inhib-
ited by the CSD antibody, but not preimmune serum, sug-
gesting that the major complexes forming on each strand
contain CSD proteins (Fig. 2B). To indicate whether dbpB
participates in formation of either of the complexes, we
added a competitor oligonucleotide that has previously been
demonstrated to bind dbpB [9]. This oligonucleotide
(GM), which is derived from the promoter of the GM-
CSF gene, competed for complex formation on the V5+
probe, but not on the V5 probe (Fig. 2C), indicating that
dbpB binds the HRR coding strand, but not the non-coding
strand, consistent with the binding preference observed for
recombinant dbpB (Fig. 2A).
Based on previous ﬁndings of binding site preferences for
CSD proteins [8,9] we introduced point mutations into the
HRR coding and non-coding strand probes and examined
the eﬀect on binding of recombinant CSD proteins or MCF-
7 nuclear extracts. Replacement of 5 0CCTG3 0 in the non-cod-
ing strand with 5 0AGAC3 0 (probe V7) reduced the binding of
recombinant GST-dbpA, and correlating with this also re-
duced the formation of the upper band of the two bands that
Fig. 2. Strand-speciﬁc binding of dbpA and dbpB CSD proteins to the human VEGF HRR (A) Gel shift assays of GST-dbpA and GST-dbpB with
32P-labelled VEGF HRR coding (V5+) and non-coding (V5) single-strand DNA probes. (B) Gel shift assays of nuclear extracts from MCF-7 cells
that had been preincubated with preimmune serum (PI), with a pan-speciﬁc anti-CSD antibody (CSD) or left untreated (), binding to 32P-labelled
VEGF HRR coding (V5+) and non-coding (V5) single-strand DNA probes. (C) Gel shift competition assays of MCF-7 nuclear extracts that had
been preincubated with unlabelled VEGF HRR coding stand (V5+), VEGF HRR non-coding strand (V5) or an oligonucleotide from the GM-CSF
gene (GM-) that binds dbpB [9]. (D) Gel shift assays of GST-dbpA or GST-dbpB or MCF-7 nuclear extracts binding to 32P-labelled wild type (V5)
and mutant (V7,V17) VEGF HRR non-coding () and coding (+) strand DNA probes. A schematic of the VEGF HRR showing HIF-1 and
predicted CSD protein binding sites is given below, with mutated regions indicated with an X.
5374 L.S. Coles et al. / FEBS Letters 579 (2005) 5372–5378form on the coding strand probe in the presence of nuclear ex-
tract (Fig. 2D). Replacement of 5 0TTC3 0 in the upper strand
probe with 5 0GAA3 0 (probe V17+) reduced the binding of re-
combinant dbpB and eliminated the formation of complexesfrom nuclear extract (Fig. 2D). Together these data indicate
that both recombinant and nuclear dbpA binds the upper
strand of the HRR in vitro, and recombinant and nuclear
dbpB binds the lower strand.
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pathway in normoxic MCF-7 cells
To test the function of the dbpA and dbpB binding sites
in the human VEGF HRR, the HRR was inserted upstream
of the minimal thymidine kinase promoter of a luciferase re-
porter gene and the eﬀect of mutation of the dbpA or dbpB
binding sites on luciferase expression in transfected MCF-7
cells was determined. Mutation of either site resulted in in-
creased expression under normoxia (Fig. 3), consistent with
our previous report that CSD proteins act as repressors of
VEGF transcription in mouse ﬁbroblasts [8]. The eﬀect of
CSD protein binding in hypoxia could not be tested by
mutation of the sites, because they overlap the site for a
positively acting hypoxia ancillary factor [13]. To test
whether dbpA and dbpB can each act as repressors, expres-
sion vectors for each were cotransfected with the VEGF
HRR-luc reporter gene, hV5luc. Coexpression of dbpA re-
duced luciferase activity by 60–63%, while coexpression of
dbpB reduced expression by 45% in normoxia, and by
67% in hypoxia (Fig. 3B), consistent with both proteins
being able to repress transcription from the VEGF HRR.
Because the ERK/MAPK and PI3K pathways have both
been found to inﬂuence VEGF expression [1,3,14], we tested
whether these pathways inﬂuence the expression of luciferase
from the VEGF HRR-luc reporter. Addition of the ERKFig. 3. Role of CSD binding sites and signalling pathways in repression of the
type (phV5luc) and mutant VEGF HRR reporter constructs. (B) Eﬀect of cot
expression from the VEGF HRR. (C) Eﬀect of the PI3K pathway inhibitor
from the VEGF HRR. The inhibitors did not aﬀect expression from the back
expression from phV5luc (data not shown).pathway inhibitor PD98059 for 16 h prior to harvest resulted
in 2.6-fold and 2.2-fold increases in luciferase expression in
normoxia and during hypoxia (Fig. 3C). This suggests that
the ERK pathway, even in unstimulated cells, maintains the
activity of a repressor of the VEGF HRR. Treatment with
the PI3K pathway inhibitor, LY294002, had little eﬀect on
luciferase expression in normoxic cells, but caused a substan-
tial reduction in expression in hypoxic cells (Fig. 3C). This
indicates that activation of the PI3K pathway contributes to
transcription from the VEGF HRR in hypoxic MCF-7 cells.
3.3. CSD protein phosphorylation by ERK2 and GSK3b and
enhanced binding of dbpB to the VEGF HR region
Given the repressive action of the ERK pathway on expres-
sion from the HRR, we wished to assess whether the dbpA or
dbpB repressor proteins might be targets for ERK pathway ki-
nases. We noticed that both dbpA and dbpB contain potential
phosphorylation sites [15,16] for ERK1/2 in their N-terminal
regions, and that the potential ERK sites in each protein had
adjacent consensus sequences for phosphorylation by GSK3b
(Fig. 4), a kinase that is negatively regulated by the PI3K path-
way [17]. To indicate whether these putative phosphorylation
sites might be targets for ERK and/or GSK3b, we tested the
ability of the kinases to phosphorylate recombinant dbpA
and dbpB in vitro. Both GST-dbpA and GST-dbpB, but nothuman VEGF HRR in MCF-7 cells. (A) Luciferase activity from wild
ransfection of dbpA (pSGA), dbpB (pSGB) or empty vector (pSG5) on
LY294002, or the MAPK pathway inhibitor PD98059, on expression
bone luciferase vector pTK81luc, and DMSO treatment did not aﬀect
Fig. 4. Phosphorylation of dbpA and dbpB by ERK2 and GSK3b . (A) GST-dbpA and dbpB were phosphorylated in vitro using ERK2 or GSK3b
and electrophoresis on SDS/PAGE. (B) Phosphorylation of the N-terminal domains of dbpA and dbpB by ERK2 and GSK3b. Auto-phosphorylated
proteins, present in GSK3b assays without any added recombinant protein, are indicated by asterisks. (C) Recombinant GST-peptide (ps) and
phosphorylation site mutant peptides (psmut) were assayed for phosphorylation by ERK2 and GSK3b. The N-terminal dbpA and dbpB sequences
contained in fusion proteins are shown, with ERK2 and GSK3b sites underlined. (D) Gel shift assays of GST-dbpA and GST-dbpB binding to their
respective strands of the HRR, with and without prior phosphorylation by ERK2 and GSK3b with unlabelled ATP.
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ERK2 (Fig. 4A), as was GST fusion protein containing just
the N-terminal domain of dbpA (dbpAdel1) or dbpB (dbpB-
del1) (Fig. 4B). GST-dbpB was also readily phosphorylated
in vitro by puriﬁed GSK3b, while GST-dbpA was phosphory-
lated to a lesser extent (Fig. 4A). Again, the fusion proteins
containing just the N-terminal domains were also phosphory-
lated (Fig. 4B). To test whether the predicted sites in the N-ter-
minal domains were sites of phosphorylation, we constructed
GST fusion proteins, dbpA-ps and dbpB-ps, containing short
peptides from the dbpA and dbpB N-terminal domains that in-cluded the predicted phosphorylation sites, as well as mutant
forms (dbpA-psmut, dbpB-psmut) in which the serine or thre-
onine residues at the predicted phosphorylation sites were
changed to alanine (Fig. 4C). The fusion proteins containing
the wild type peptide regions were phosphorylated by ERK2
and GSK3b in vitro, but phosphorylation was reduced or
abolished by mutation of the predicted ERK2 and GSK3b
sites (Fig. 4C).
Finally, we tested whether phosphorylation of dbpA or
dbpB aﬀected their binding to the VEGF HRR in vitro.
GST-dbpA and GST-dbpB fusion proteins were phosphory-
L.S. Coles et al. / FEBS Letters 579 (2005) 5372–5378 5377lated in vitro by ERK2 or GSK3b and tested for binding to
VEGF HRR probes in a gel shift assay. Phosphorylation by
both ERK2 and GSK3b increased the binding of dbpB to
the VEGF HRR coding strand, but did not appreciably
aﬀect the binding of dbpA to the non-coding strand
(Fig. 4D). Binding of each protein to the opposite strands re-
mained negligible (data not shown). Phosphorylation of
dbpB may therefore regulate its binding to the VEGF
HRR. The increase in DNA binding by ERK2 phosphoryla-
tion is consistent with our ﬁnding that the ERK pathway
inhibitor, PD98059, increases expression from the VEGF
HRR, while the increase in DNA binding by GSK3b is con-
sistent with its proposed involvement in repression of VEGF
HRR activity [4,18].4. Discussion
The binding of CSD proteins to single-strand DNA is
thought to play a major role in repression by these proteins
and is proposed to block the binding of activator factors that
require double-strand DNA [8,9,19–21]. Sequence-speciﬁc sin-
gle-strand DNA binding is directed by a central conserved 70
amino acid CSD domain [22] but can be modulated by the
ﬂanking N-terminal sequences [23,24]. The binding of CSD
protein complexes to both strands of the human VEGF
HRR may secure the region in a stable single-stranded repres-
sive structure that prevents inappropriate activation of this re-
gion under unstimulated conditions.
We found that CSD proteins are targets for signalling
pathways that regulate the activity of the VEGF HRR in
MCF-7 cells. We demonstrate for the ﬁrst time that dbpA
and dbpB/YB-1 can be phosphorylated by ERK2, which is
positively regulated by the MAPK pathway [15], and also
by GSK3b which is negatively regulated by the PI3K path-
way [25]. GSK3b is constitutively active in unstimulated cells
and is inactivated in hypoxic conditions by PI3K pathway-
activated Akt [25]. Conceivably, a reduction in CSD protein
phosphorylation on activation of the PI3K/Akt pathway
could augment the eﬀect this pathway has in some cell types
in increasing HIF-1 activity during hypoxia [26] or in re-
sponse to growth factors [2]. We found that the binding of
dbpB/YB-1 to the VEGF HR region coding (+) strand
DNA was enhanced by both GSK3b and ERK2 phosphory-
lation and the binding of dbpA to the non-coding () strand
was slightly enhanced by ERK2 phosphorylation. GSK3b
and ERK2 may therefore play a role in increasing CSD pro-
tein binding to the VEGF promoter and may enhance the
repressive ability of these proteins, although further work is
required to verify that the CSD proteins are phosphorylated
in vivo by ERK and GSK3. Although phosphorylation of
dbpA had little eﬀect on DNA binding of the recombinant
protein, it cannot be ruled out that phosphorylation plays a
role in nuclear dbpA complex formation. We observed that
recombinant dbpA binds poorly compared to the CSD pro-
tein-containing nuclear complex that forms on the non-cod-
ing strand, and it is possible that phosphorylation may
contribute to this diﬀerence. Phosphorylation may also be in-
volved in cross talk between the CSD complexes binding to
the two VEGF HRR strands, to assist in stabilizing a repres-
sive single-strand structure.An interesting parallel to the mode of action of dbpB in
repressing the VEGF gene, and the potential regulation by
phosphorylation, has been described in a report on the regula-
tion of thyrotropin gene transcription by the rat dbpB/YB-1
homologue, TSEP-1 [27]. TSEP-1 binds to single-stranded mo-
tifs in the thyrotropin gene promoter and is a repressor of thy-
rotropin receptor gene transcription. In addition, the binding
of TSEP-1 in vitro was found to be enhanced by prior
in vitro phosphorylation by protein kinase A. YB-1 has also
been shown to be phosphorylated in vitro by casein kinase II
[28], which may participate in regulating its nuclear transloca-
tion [29].
We found that the MAPK pathway in MCF-7 cells represses
expression from the VEGF HRR, in apparent contrast to a
number of reports that show the MAPK pathway activates
expression from HRE-containing reporter genes [30–32,18].
In some cases the diﬀerence may simply be due to the use in
the reporter of the erythropoietin HRE [30–32], which does
not contain obvious sites for binding CSD proteins. Neverthe-
less, it is established in a number of cell types that activation of
the MAPK pathway leads to increased HIF-1a transactivating
activity [30–32,18], although the degree to which the MAPK
pathway aﬀects HIF-1a is known to vary between diﬀerent cell
lines [3]. It is possible that the overall outcome in each cell type
depends on the balance of contributions from the opposing ef-
fects of enhanced repression by CSD proteins on the one hand
and enhanced transactivating activity of HIF-1 on the other.
The only other report we are aware of that indicates repression
of VEGF expression by a MAPK pathway is the ﬁnding that
the ERK5 MAPK acts as a repressor of VEGF in mouse
embryonic ﬁbroblasts [33]. It would be interesting to determine
whether the CSD proteins are substrates for ERK5. The eﬀect
of the MAPK pathway we observed in normoxia is consistent
with reports demonstrating the presence of activated/phos-
phorylated ERK1/2 in both stimulated and unstimulated
MCF-7 cells [34].
We localized phosphorylation sites for GSK3b and ERK2 to
the N-terminal regions of dbpA and dbpB/YB-1. Examination
of the protein sequences revealed potential ERK2 [25,35] and
GSK3b [15,16] phosphorylation sites within the N-terminal re-
gions of dbpA and dbpB/YB-1, but no apparent sites in the
CSD or C-terminal domains. Mutation of the predicted sites
conﬁrmed that they are targets for the two kinases. Consistent
with the observed eﬀect of CSD protein phosphorylation on
DNA binding (primarily on dbpB/YB-1), CSD protein N-ter-
minal regions have been shown to aﬀect the eﬃciency of CSD
protein binding to single-strand DNA [36,23]. Taken all to-
gether, our data suggest that in normoxic conditions the bind-
ing of dbpA and dbpB/YB-1 to each strand of the VEGF HR
region results in eﬃcient repression, presumably by the crea-
tion of a stable single-strand structure which would inhibit
the binding of activators that require double-strand DNA.
The CSD proteins would therefore function to maintain the
HR region in a repressed state in the absence of activating
stimuli. Phosphorylation by ERK and GSK3b in normoxic
cells would contribute to the stabilization of CSD proteins
binding to single strand DNA, in particular to the binding
by dbpB/YB-1. Under hypoxic conditions CSD protein bind-
ing may be reduced by the loss of GSK3b phosphorylation,
allowing displacement of CSD proteins and the binding of
double-strand DNA-dependent hypoxic activators such as
HIF.
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